COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) |
1 Months Ended | 12 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|
Oct. 04, 2023 |
Feb. 02, 2023 |
Jan. 11, 2022 |
May 30, 2019 |
Dec. 31, 2023 |
Dec. 31, 2022 |
Sep. 30, 2019 |
Dec. 10, 2015 |
|
| First payment owed | $ 145,000 | $ 0 | ||||||
| Accrued interest | 57,412 | |||||||
| Recognized loss on contingency | $ (322,000) | |||||||
| Compensation for services, description | As of May 14, 2021, the Company has entered into four consulting agreements. In compensation for services: (i) one consultant shall receive a renumeration amount of $10,000-$12,500 per month and has earned 1% of the Company’s majority owned subsidiary, BioCorRx Pharmaceuticals as of May 7, 2021 based on FDA clearance of Company’s IND application; consulting agreement terminated in April 2021 (ii) one consultant shall receive common stock equivalent to $1,375 on the last day of each month; (iii) two consultants shall receive common stock equivalent to $3,750 on the last day of each month; and (iv) one consultant shall receive a remuneration amount of $3,500 per month | |||||||
| Charles River Laboratories, Inc. [Member] | ||||||||
| Remaining commitment | $ 28,936 | |||||||
| Payment of amended consideration | $ 3,024,476 | |||||||
| BICX Holding Company LLC [Member] | ||||||||
| Common stock issued upon convertible debt | 2,227,575 | |||||||
| Convertible Promissory Note | $ 4,160,000 | |||||||
| Conversion agreement description | Pursuant to the Conversion Agreement, BICX has agreed that the Total Interest Payment (as defined in the Conversion Agreement) that would have been due under the Note, in the amount of $1,138,157, will be reflected on the Company’s financial statements as an amount due and owing to the Investor to be repaid within twelve (12) months of the closing of the Public Offering, or if the Public Offering is terminated or abandoned prior to closing, then on or before such date that is no later than twelve (12) months from the date of such termination or abandonment. As of December 31, 2023, the Public Offering has not yet been abandoned by the Company | |||||||
| Issuance price | $ 2.00 | |||||||
| Orange County Research Center [Member] | ||||||||
| Consideration amount | $ 657,640 | $ 503,089 | ||||||
| Pellecome [Member] | ||||||||
| Attorney's fees | $ 235,886 | |||||||
| Attorney's fees received or awarded | $ 222,933 | $ 222,933 | ||||||
| Interest rate | 10.00% | |||||||
| Pellecome [Member] | January 5, 2024 [Member] | ||||||||
| Attorney's fees received or awarded | $ 332,503 | |||||||
| Consultant [Member] | ||||||||
| Issue of common stock to consultant | 3,000 | |||||||
| Renumeration amount | $ 1,417 | |||||||
| Alpine Creek [Member] | ||||||||
| Royalty due | 91 | $ 91 | ||||||
| Total consideration amount | 1,531,926 | |||||||
| Payables to Alpine Creek | $ 1,215,000 | |||||||
| Paid to Alpine Creek | $ 1,620,000 | |||||||
| Payable commitment description | On any other proprietary implant distribution, that excludes the “treatment”, for alcohol and opioid addiction and for which no other payment is due, the Company shall pay 2.5% of the Company’s gross profit for implant distribution not to exceed $100 per sale. On or about January 1, 2021, Mr. Galligan acquired from Alpine Creek the rights to the royalty agreement by and between the Company and Alpine Creek. As of December 31, 2023 and 2022, there are no payments due | |||||||
| Payable per treatment sold | $ 100 | |||||||
| Profit holding percentage | 50.00% | |||||||
| Board Member [Member] | ||||||||
| Receive common stock equivalent | $ 5,000 |